Press release
August 13, 2026
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Parabilis Medicines, Inc. (PBLS)
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary